Profile data is unavailable for this security.
About the company
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
- Revenue in USD (TTM)5.00m
- Net income in USD-54.07m
- Incorporated2018
- Employees127.00
- LocationAdlai Nortye Ltdc/o Ugland HousePO Box 309GRAND CAYMAN KY1-1104Cayman IslandsCYM
- Phone+1 8 482307430
- Websitehttp://www.adlainortye.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Spero Therapeutics Inc | 118.46m | 17.46m | 73.24m | 46.00 | 4.28 | 0.9091 | 4.15 | 0.6182 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
Gritstone bio Inc | 14.61m | -133.03m | 73.84m | 231.00 | -- | 3.32 | -- | 5.05 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
Tevogen Bio Holdings Inc | 0.00 | 57.92m | 75.08m | 17.00 | 1.17 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 77.49m | 127.00 | -- | 1.45 | -- | 15.50 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
PMV Pharmaceuticals Inc | 0.00 | -48.88m | 78.31m | 63.00 | -- | 0.3654 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Omega Therapeutics Inc | 6.31m | -78.90m | 78.32m | 93.00 | -- | 2.98 | -- | 12.40 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
IO Biotech Inc | 0.00 | -88.00m | 78.40m | 68.00 | -- | 0.8143 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
Chimerix Inc | 144.00k | -84.70m | 78.43m | 72.00 | -- | 0.5041 | -- | 544.68 | -0.9507 | -0.9507 | 0.0016 | 1.74 | 0.0007 | -- | 1.86 | 2,000.00 | -40.37 | -30.45 | -44.33 | -34.09 | 10.42 | -- | -58,820.14 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
Sellas Life Sciences Group Inc | 0.00 | -34.44m | 78.49m | 16.00 | -- | 24.19 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
Renovaro Inc | 0.00 | -88.12m | 79.21m | 11.00 | -- | 0.4698 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Armata Pharmaceuticals Inc | 3.72m | -67.04m | 80.69m | 66.00 | -- | -- | -- | 21.70 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
Vistagen Therapeutics Inc | 970.40k | -33.19m | 81.17m | 41.00 | -- | 0.7745 | -- | 83.64 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
Genelux Corp | 8.00k | -26.54m | 81.85m | 23.00 | -- | 2.14 | -- | 10,231.13 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 82.37m | 12.00 | -- | 8.11 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Cantor Fitzgerald & Co.as of 30 Jun 2024 | 40.31k | 0.04% |
Millennium Management LLCas of 30 Jun 2024 | 18.65k | 0.02% |
Qube Research & Technologies Ltd.as of 30 Jun 2024 | 88.00 | 0.00% |